login
  Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

“We will see steady progress in percutaneous mitral valve therapy over the next couple of years”


Thursday, 15 Mar 2012 11:18
Ted Feldman
Ted Feldman

Catheter-based mitral valve repair with MitraClip is the best-studied type of percutaneous mitral valve therapy, said Ted Feldman, Evanston Hospital, NorthShore University Health System, Evanston, USA, at the International Symposium on Endovascular Therapy (ISET) in Miami.


The EVEREST II (Endovascular valve edge-to-edge repair study) study assessed the safety and effectiveness of the MitraClip device (Abbott Vascular) in patients with significant mitral regurgitation at high risk of surgical mortality rate. The study, published by Feldman et al (N Engl J Med 2011;364:1395–1406), concluded that although percutaneous repair with the MitraClip device “was less effective at reducing mitral regurgitation than conventional surgery, the procedure was associated with superior safety and similar improvements in clinical outcomes.”


A substudy was done on high risk patients. An analysis of the acute and 12-month results of 78 patients showed that the survival rate at one year was 76% in the high risk study and 55% in the concurrent comparator group (p=0.047) of screened concurrently but not enrolled patients.


Feldman showed delegates research behind various other mitral valve devices, including the Carillon Mitral Contour System (Cardiac Dimensions). The TITAN trial showed 40% reduction in mitral regurgitation, improvements in reverse remodeling and functional improvement in patients implanted with the device. “Outcomes in terms of reduced mitral regurgitation and improved chamber function are notable,” he said.


The future of the field may be direct annuloplasty using different delivery devices, including the transventricular approach, which is used in the Mitralign Percutaneous Annuloplasty System or the Guided Delivery System, Feldman said. In this transcatheter procedure, surgical implants are placed directly into the mitral annulus and tensioned through a catheter to reduce the annular circumference, thus mimicking the surgical techniques.


One of the most interesting devices is the Myocor Surgical Coapsys System, he said. This is a novel approach that uses a cathether passed through the left ventricle to reshape the left ventricle and reduce the mitral regurgitation. In the RESTOR-MV (Randomized evaluation of a surgical treatment for off-pump repair of the mitral valve) trial, the system was shown to reduce mortality. The investigators concluded that “patients with functional mitral regurgitation requiring revascularisation treated with ventricular reshaping rather than standard surgery had improved survival and a significant decrease in major adverse outcomes. This trial validates the concept of the ventricular reshaping strategy in this subset of patients with heart failure.”


Another innovation in the field is transcatheter mitral valve replacement, Feldman noted. This approach will use a catheter to deliver a new mitral valve. The major challenge for valve replacement is anchoring of the new valve in the native annulus.


“There is a lot happening in the field, and we will see steady progress over the next couple of years,” Feldman concluded.




Add New Comment

Related Items


Most popular


Drug-coated balloons are not inferior to drug-eluting stents for treating stent restenosis
Friday, 06 Mar 2015
A retrospective study indicates that drug-coated balloons are associated with similar angiographic and clinical outcomes to drug-eluting stents (including both first- and second-generation stents) ... Drug-coated balloons are not inferior to drug-eluting stents for treating stent restenosis

Thursday, 26 Feb 2015
Vitaria delivers autonomic regulation therapy for patients who have moderate to severe heart failure with left ventricular dysfunction (ejection fraction < 40%), and who remain symptomatic despite ... Vitaria vagal nerve stimulation system receives CE mark for treatment of chronic heart failure

Boston Scientific receives FDA approval for Watchman left atrial appendage closure device
Monday, 16 Mar 2015
The device offers an alternative to long-term warfarin therapy for stroke risk reduction in patients with non-valvular atrial fibrillation. Boston Scientific receives FDA approval for Watchman left atrial appendage closure device

Features


Robotic PCI could be used to reduce radiation exposure to the operator
Thursday, 09 Apr 2015
Ryan Madder, an interventional cardiologist at the Frederik Meijer Heart & Vascular Institute (Spectrum Health, Grand Rapids, Michigan, USA) explains why he believes a robotic system (CorPath, C... Robotic PCI could be used to reduce radiation exposure to the operator

SERVE-HF could be a wake-up call for cardiologists about central sleep apnoea
Tuesday, 24 Mar 2015
Martin Cowie (Imperial College London, London, UK) is the principal investigator of the SERVE-HF study, which is assessing the use of adaptive servo-ventilation (PaceWave, ResMed) in chronic heart ... SERVE-HF could be a wake-up call for cardiologists about central sleep apnoea

Profiles


Flavio Ribichini
Thursday, 05 Mar 2015
Flavio Ribichini speaks to Cardiovascular News about being involved in the first use of primary ... Flavio Ribichini

Sunil Rao
Thursday, 23 Oct 2014
Sunil Rao speaks to Cardiovascular News about his career highlights, including his research into ... Sunil Rao

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions